Trade: FDA approves argenx's Vyvgart?

Market context

The FDA is scheduled to decide on argenx's application to expand Vyvgart's indication to seronegative generalised myasthenia gravis (gMG) by 10 May 2026. Vyvgart (efgartigimod) is already approved for seropositive gMG, having received FDA clearance in December 2021. The current application seeks to extend use to seronegative patients, who represent roughly 10–15% of the gMG population. The 100% implied probability on Polymarket's order book reflects market confidence in approval, though this represents a compressed risk assessment given the compressed timeline and the precedent of the drug's existing safety and efficacy profile in the seropositive indication.

Regulatory precedent suggests high approval likelihood. The FDA has historically approved indication expansions for monoclonal antibodies and complement inhibitors targeting autoimmune conditions when clinical data demonstrate efficacy in new patient subsets. Argenx's Phase 3 trial data for seronegative gMG, presented at major neurology conferences, showed statistically significant improvements in muscle strength measures. The company's track record with the seropositive indication and established manufacturing infrastructure reduce regulatory friction compared to novel drug applications.

Key catalysts include any FDA communications requesting additional data before the decision date, which would signal potential delays beyond May 2026. Traders should monitor argenx's quarterly earnings calls and clinical updates for any mention of FDA interactions. The settlement window extends to 24 May 2026, allowing a two-week buffer beyond the expected decision date for administrative processing. Approval timing could shift if the FDA issues a complete response letter requesting supplemental data, though current market pricing suggests traders assess this risk as minimal.

How this market resolves

Resolution is handled by the UMA optimistic oracle on Polygon. A proposer submits the outcome, a two-hour dispute window opens, and if no one stakes a counter-claim the payout is final. Contested outcomes escalate to UMA token-holder voting. Payouts clear in USDC to the winning side.

How to trade this market step by step

The mechanics for trading "FDA approves argenx's Vyvgart?" are the same as any other PolyGram event contract. Each YES share resolves to $1 if the event happens, or $0 if it doesn't. The current price between 0¢ and 100¢ is the market's probability estimate, set live by the order book.

1. Sign in on polygram.ink with your email — no full KYC under $1,500 lifetime trading volume.
2. Deposit USDC on Polygon (lowest fees, ~$0.01 per transaction) or Ethereum. Funds credit after 12 confirmations.
3. Pick a side. Buy YES if you believe the event will happen; buy NO if you think it won't. The current YES price reflects the market's collective probability.
4. Size your position. If you stake 100 USDC at 100% YES, you'll receive shares that pay $100 if YES resolves true — a 0% gross return. If NO resolves, your shares are worth $0.
5. Set risk controls (optional). Stop-loss, take-profit, and limit-order types all supported. Use the trade ticket's slippage box to cap your maximum entry price.
6. Wait for resolution. When the event resolves on-chain via the UMA optimistic oracle, the winning side settles to 100¢ automatically and USDC hits your balance within seconds. Withdrawable to any wallet you control.

How active is this market?

$10K in lifetime turnover and $0 of resting liquidity puts this market in the below the median by volume for drug contracts on PolyGram. Order-book depth is thin — large orders may need to be split across the book or executed as limit orders.

The market has been open for under a month — fresh enough that information asymmetry remains a real factor.

Higher-volume markets tend to have tighter spreads and faster price discovery — meaning the displayed YES/NO percentages are more likely to reflect the true crowd-implied probability rather than a single trader's directional view.

Key terms

YES / NO share

A binary outcome token that pays $1.00 if the underlying claim resolves true (YES) or false (NO), and $0 otherwise. The market price between 0¢ and 100¢ is the implied probability.

CLOB

Central limit order book. The matching engine that pairs YES buyers with NO buyers (effectively the same trade). Polymarket's CLOB on Polygon executes trades on-chain via the conditional-tokens framework.

Liquidity

USDC capital sitting in resting limit orders inside the order book. Deeper liquidity means smaller slippage on large trades and a tighter bid-ask spread.

UMA optimistic oracle

The on-chain dispute system that settles each Polymarket market. A proposer submits the outcome, a two-hour challenge window opens, and unchallenged proposals finalise the resolution.

Slippage

The difference between the displayed mid-price and your fill price. Affects market orders most; limit orders avoid slippage but may take time to fill.

Conditional token

ERC-1155 outcome share issued by Gnosis Conditional Tokens on Polygon. The token type that resolves to $1.00 or $0.00 at settlement.

See the full prediction-market glossary →

Frequently asked questions

Risk and regulatory note

Prediction-market positions can lose 100% of staked capital. Outcomes are uncertain by definition — historical accuracy of crowd-implied probabilities is high in aggregate but not for any single market. PolyGram does not provide investment advice. Trade only with capital you can afford to lose.

Regulatory status varies by jurisdiction. Germany, the United States, and most EU countries treat Polymarket-style event contracts under one of three frameworks: financial derivative, gambling product, or unregulated novel asset. Consult local counsel before trading.

Related prediction markets

Explore more prediction market odds and trading opportunities on PolyGram:

• All drug prediction markets
• How prediction markets work
• Browse all prediction markets on PolyGram
• Top prediction market traders
• Back to PolyGram home